- Home
- FIVE vs HALO Comparison
FIVE vs HALO Comparison
Compare FIVE & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- HALO
- Stock Information
- Founded
- FIVE 2002
- HALO 1998
- Country
- FIVE United States
- HALO United States
- Employees
- FIVE N/A
- HALO N/A
- Industry
- FIVE Department/Specialty Retail Stores
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FIVE Consumer Discretionary
- HALO Health Care
- Exchange
- FIVE Nasdaq
- HALO Nasdaq
- Market Cap
- FIVE 8.4B
- HALO 7.6B
- IPO Year
- FIVE 2012
- HALO N/A
- Fundamental
- Price
- FIVE $154.37
- HALO $66.96
- Analyst Decision
- FIVE Buy
- HALO Buy
- Analyst Count
- FIVE 18
- HALO 11
- Target Price
- FIVE $147.53
- HALO $73.09
- AVG Volume (30 Days)
- FIVE 1.2M
- HALO 2.2M
- Earning Date
- FIVE 12-03-2025
- HALO 11-04-2025
- Dividend Yield
- FIVE N/A
- HALO N/A
- EPS Growth
- FIVE N/A
- HALO 68.93
- EPS
- FIVE 4.95
- HALO 4.37
- Revenue
- FIVE $4,231,969,000.00
- HALO $1,178,672,000.00
- Revenue This Year
- FIVE $19.41
- HALO $32.57
- Revenue Next Year
- FIVE $9.81
- HALO $23.77
- P/E Ratio
- FIVE $31.18
- HALO $15.35
- Revenue Growth
- FIVE 13.88
- HALO 34.97
- 52 Week Low
- FIVE $52.38
- HALO $42.01
- 52 Week High
- FIVE $157.54
- HALO $79.50
- Technical
- Relative Strength Index (RSI)
- FIVE 54.56
- HALO 41.47
- Support Level
- FIVE $149.37
- HALO $63.80
- Resistance Level
- FIVE $155.30
- HALO $68.00
- Average True Range (ATR)
- FIVE 5.85
- HALO 2.30
- MACD
- FIVE -0.42
- HALO -0.48
- Stochastic Oscillator
- FIVE 83.63
- HALO 25.24
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.